RxDoctor Payments DataLook up a doctor →

Pavel Klein, MD

Neurology · Bethesda, MDNPI 1770528648

Payments from drug & device makers

$3,244,041in general payments, 2019–2025

Across 1,458 payments — averaging $2224.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$1.2M
  • Neurelis, Inc.$415K
  • UCB SA$337K
  • Eisai Inc.$258K
  • Daiichi Sankyo Inc.$223K
  • Takeda Pharmaceuticals U.S.A., Inc.$206K
  • plus $574K from 45 others
$83,840in research payments, 2019–2025

Across 29 payments — averaging $2891.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Aquestive Therapeutics, Inc.$51K
  • UCB, Inc.$31K
  • UCB SA$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.395$1,230,619
Neurelis, Inc.81$415,033
UCB SA59$336,961
Eisai Inc.181$258,499
Daiichi Sankyo Inc.105$223,168
Takeda Pharmaceuticals U.S.A., Inc.32$205,537
UCB, Inc.237$170,309
Lundbeck LLC3$92,644
Immedica Pharma US, Inc.12$58,836
Biogen10$50,375
Zogenix Inc.4$35,963
Janssen Research & Development, LLC6$26,076
Jazz Pharmaceuticals Inc.22$26,012
Dr.reddy's Laboratories,inc.13$24,367
Aquestive Therapeutics, Inc.49$21,525
Greenwich Biosciences, Inc.25$13,900
Sunovion Pharmaceuticals Inc.65$13,215
Zevra Therapeutics Inc1$10,250
AbbVie(2 entities)7$9,753
UCB Biosciences Inc.10$9,349
H. Lundbeck A S26$4,534
Neurocrine Biosciences, Inc.6$2,666
Otter Pharmaceuticals, LLC1$1,410
Shire North American Group Inc1$400
Novartis14$294
Supernus Pharmaceuticals, Inc.11$232
Teva Pharmaceuticals USA, Inc.2$218
Sumitomo Pharma America, Inc.16$209
Neuropace, Inc.4$183
AstraZeneca3$159
Axsome Therapeutics, Inc.3$139
Inspire Medical Systems, Inc.1$137
Livanova USA, Inc.6$123
Upsher-smith Laboratories LLC6$109
Lilly USA, LLC6$104
Avanir Pharmaceuticals, Inc.3$100
Sanofi5$98
Bristol Myers Squibb5$84
EMD Serono, Inc.4$76
Amgen3$67
Kyowa Kirin, Inc.2$43
Argenx US, Inc.2$39
Adamas Pharmaceuticals, Inc.2$39
Biocodex, Inc.2$35
Banner Life Sciences, LLC1$30
Aucta Pharmaceuticals, Inc.1$27
Mallinckrodt Hospital Products Inc.1$24
Idorsia Pharmaceuticals US Inc1$24
Biohaven Pharmaceutical Holding Company Ltd.1$20
Catalyst Pharmaceuticals, Inc.1$17
E.r. Squibb & Sons, L.L.C.1$12

How this compares

$3,244,041 in reported general payments places this provider in the 95th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland →

Medicare billing

Part B allowed, 2024
$620,277
Medicare patients
1,479
Services billed
4,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Bethesda

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →